StemCells, Inc. is currently engaged in clinical development of its proprietary HuCNS-SC® (purified human neural stem cells) platform technology to treat diseases of the human central nervous system (CNS).
NASDAQ :STEM
StemCells, Inc. is currently engaged in clinical development of its proprietary HuCNS-SC® (purified human neural stem cells) platform technology to treat diseases of the human central nervous system (CNS).